萬泰生物(603392.SH):艾滋抗體尿液自檢試劑通過WHO的PQ認證
格隆匯5月6日丨萬泰生物(603392.SH)公佈,收到世界衛生組織(簡稱“WHO”)出具的體外診斷預認證(PQ)確認函,公司的HIV尿液自檢試劑-人類免疫缺陷病毒1型尿液抗體檢測試劑盒(膠體金法)(英文名稱:HIVSELFTESTBYURINE–HumanImmunodeficiencyVirus(HIV)Type-IUrineAntibodyDiagnosticKit(ColloidalGold))已通過WHO的預認證,被WHO列入體外診斷產品預認證清單。這是繼公司的人類免疫缺陷病毒抗體診斷試劑盒(酶聯免疫法)及人類免疫缺陷病毒(HIV1+2型)抗體檢測試劑盒(膠體金法)通過WHOPQ認證後,第三款通過WHOPQ認證的HIV檢測產品,同時是全球首款獲得WHOPQ的HIV抗體尿液自檢試劑盒。標誌着公司的產品性能及質量管理體系再次獲得國際認可。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.